MedTrace Logo

Study to Compare the Safety and Pharmacokinetics of CKD-397

NCT02645890 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2016-01-12

No results posted yet for this study

Summary

The purpose of this study is to compare the safety and pharmacokinetics profiles of CKD-397 in healthy male volunteers.

Conditions

  • Benign Prostatic Hyperplasia

Interventions

DRUG

CKD-397

Arm A:Tamsulosin/ Tadalafil Fixed dose combination

DRUG

TD+TM

Arm B: Tamsulosin/ Tadalafil Coadministration

Sponsors & Collaborators

  • Chong Kun Dang Pharmaceutical

    lead INDUSTRY

Principal Investigators

  • Min Kyu Park, MD, PhD · 9F, DongA University Hospital Department of clinical pharmacology, #26, Daechingongwon-ro, seo-gu, busan, 49201, KOREA

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-11-30
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • South Korea

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02645890 on ClinicalTrials.gov